A single RSV shot emerges as a promising new shield for infants at risk of severe disease

Viral infections that attack the lungs are among the leading reasons infants are hospitalized.

A new treatment may offer protection against these infections that is as effective and safe as existing options but requires far fewer injections.

The Phase III SMART clinical trial investigated the safety and efficacy of clesrovimab (brand name ENFLONSIA), a long-acting medicine designed to protect babies from respiratory syncytial virus (RSV). ...